Fred D. Lublin, MD

Saunders Family Professor of Neurology, and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine, Mount Sinai

Articles by Fred D. Lublin, MD

CMSC Live: 2024 Annual Meeting Day 2

ByNeurologyLive® Staff,Jeffrey Wilken, PhD,Fred D. Lublin, MD,Brian Hutchinson, PT, MSCS,Robert W. Motl, PhD

May 30th 2024

Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

Future of Relapsing MS Management

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

August 14th 2021

Key opinion leaders in multiple sclerosis (MS) discuss the future of relapsing MS management and unmet needs.

Biomarkers for Monitoring Treatment Response in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

August 14th 2021

Expert neurologists discuss current and future biomarkers relevant to relapsing multiple sclerosis including cerebrospinal fluid neurofilament.

Fred Lublin, MD, Saunders Family professor of neurology, and director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center

Exciting Multiple Sclerosis Debates at IFN 2021: Fred Lublin, MD

ByFred D. Lublin, MD

August 13th 2021

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.

Shared Decision Making and Lifestyle Issues in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

August 8th 2021

A panel of experts emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.

Sequencing Therapies in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

August 8th 2021

Experts in multiple sclerosis (MS) discuss key factors involved in the sequencing of therapies for relapsing MS.

Monitoring Outcomes in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 31st 2021

Lauren Gluck, MD discusses considerations for monitoring response to treatment in relapsing multiple sclerosis.

Overview of Teriflunomide for Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 31st 2021

Lauren Gluck, MD, and Ravi Dukkipati, MD, provide an overview of teriflunomide for relapsing multiple sclerosis including its safety and tolerability profile.

Considerations for the Use of Fumarates in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 24th 2021

Experts in the field of multiple sclerosis provide insight into the fumarates as a viable oral option for relapsing MS.

Anti-CD20 Agents for Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 24th 2021

A panel of experts discuss the use of anti-CD20 monoclonal antibodies in relapsing multiple sclerosis including summaries of the phase III ORATORIO and ASCLEPIOS trials, for ocrelizumab and ofatumumab, respectively.

Role of S1P Receptor Modulators in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 18th 2021

Expert neurologists discuss the role of sphingosine-1-phosphate (S1P) receptor modulators in relapsing multiple sclerosis including vaccine considerations and pediatric use.

Cladribine in Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 18th 2021

Key opinion leaders provide insight into the use cladribine for relapsing multiple sclerosis including durability and safety profile.

Cladribine: History and Mechanism of Action in MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 11th 2021

Gavin Giovannoni, MD provides an overview of the development and pharmacodynamics of cladribine in multiple sclerosis.

Platform Agents for MS: Interferons and Glatiramer

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

July 11th 2021

Fred D. Lublin, MD, Ravi Dukkipati, MD, and Lauren Gluck, MD, discuss interferons and glatiramer as platform therapies in multiple sclerosis.

Treatment Strategy for Relapsing MS

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

June 30th 2021

Experts in multiple sclerosis (MS) provide an overview of treatment strategies and selection in relapsing MS.

The Diagnosis of Multiple Sclerosis

ByFred D. Lublin, MD,Ravi Dukkipati, MD,Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath,Lauren Gluck, MD

June 30th 2021

Fred D. Lublin, MD discusses the diagnosis of multiple sclerosis and the 2017 revisions of the McDonald criteria.

Advice for Managing MS

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

May 13th 2021

Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.

Future of MS Management

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

May 6th 2021

Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management.

Exercise and MS Fatigue

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

May 6th 2021

Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.

MS: Nutrition and Managing Cognitive Impairment

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 29th 2021

The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment.

Shared Decision-Making and Complementary Therapies in Progressive MS

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 29th 2021

Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.

Age Considerations: Patients With Nonactive MS Progression

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 22nd 2021

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

Monitoring Response in Progressive MS

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 22nd 2021

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Ibudilast for Progressive Treatment

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 15th 2021

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

Nonactive MS: Treatment Therapies

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 15th 2021

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

Patient Selection in MS Treatment

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 8th 2021

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Progressive MS Treatment: Ocrelizumab

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 8th 2021

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.

MS Treatment: EXPAND Study Versus ASCEND Study

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 1st 2021

Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.

Siponimod for SPMS Treatment

ByBruce Cree, MD, PhD, MAS, FAAN,Joseph R. Berger, MD,Kristen Krysko, MD,Fred D. Lublin, MD,Robert Fox, MD

April 1st 2021

Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.